This study is for subjects that have been diagnosed with advanced high grade serious ovarian cancer. The investigational drug used in this study is Sovilnesib. The main purpose of this study is to is to establish the recommended phase 2 dose, which will be considered the optimal dose, of Sovilnesib. Additionally, this study will examine the safety, tolerability and preliminary efficacy of Sovlinesib. The total time you will be on the study treatment will depend on if you have any unwanted side effects and how your cancer is responding to treatment.

This study will evaluate the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with Claudin 6 (CLDN6)-positive locally advanced or metastatic solid tumors. The primary objectives for this study in part 1 is to evaluate the safety and tolerability of SAIL66 and to determine the maximum tolerated dose (MTD) or maximum administered dos(MAD) and the recommended dose (RD) of SAIL66. In part 2 it is to evaluate the preliminary anti-tumor activity of SAIL66 when administered at
selected dose(s) in each cohort and o evaluate the safety of SAIL66 when administered at selected dose(s).

This study is for patients that have been diagnosed with high grade serous or endometroid epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The main purpose of this study is to find out if giving heated chemotherapy into the belly, known as heated intraperitoneal chemotherapy (HIPEC), improves the treatment of this type of cancer. Participants can expect to be in the study for up to 40 months.

This study is for patients that have been diagnosed with Advanced/Recurrent Endometrial cancer and have responded to chemotherapy treatment. The investigational drug used in this study is Navtemadlin.The main purpose of this study is to determine if Navtemadlin is well-tolerated and effective at treating endometrial cancer. Patients can expect to be in this study for up to 24 months.

This study is for subjects with endometrial cancer has spread to other parts of your body and/or has not responded to previous treatment(s). The study is being done to see if combining two immunotherapy drugs, nivolumab and ipilimumab, more effective in shrinking their cancer and preventing its growth than single drug immunotherapy with nivolumab alone. The subject can expect to be in this study for up to 24 months.

The purpose of this study is to learn about the effects of an experimental treatment called E7386. This study is for patients with hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumors. E7386 in combination with levantinib fight tumors by decreasing tumor density. The purpose of this study is to learn about the effects of an experimental treatment called E7386. E7386 is considered "experimental" because it has not been approved by the U.S. Food & Drug Administration (FDA) for the treatment of any disease. Levantinib is FDA approved and has been previously used to treat cancer, however, it is considered experimental in combination with E7386.

This study is for subjects that have been diagnosed with advanced solid cancer tumors or relapsed prostate cancer. The investigational drugs in this study are hydroxychloroquine, nelfinavir, metformin, dasatinib and sirolimus. The purpose of this study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of cancer. Subjects can expect to be in this study for about 2.5 years.